On April 26, 2022 ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported that the Company will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 2:30 p.m. Eastern Time (Press release, ESSA, APR 26, 2022, View Source;co-healthcare-investor-conference-301533609.html [SID1234612978]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

David. R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings. Peter Virsik, ESSA’s Chief Operating Officer, and David S. Wood, ESSA’s Chief Financial Officer, will also be participating in the one-on-one meetings.

About the Bloom Burton & Co. Healthcare Investor Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

On April 26, 2022 Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, reported that the Company will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario on Monday, May 2, 2022 at 3:30 p.m. ET (Press release, Fusion Pharmaceuticals, APR 26, 2022, View Source;co-healthcare-investor-conference-301533624.html [SID1234612995]). Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 60 days following the presentation.

On April 26, 2022 KYORIN Holdings, Inc., reported that, the Company made the following revisions to the consolidated earnings forecasts for the fiscal year ended March 31, 2022 disclosed on May 11, 2021 (at the time of the financial results announcement) based on the current business performance (Press release, Kyorin, APR 26, 2022, View Source [SID1234612945]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Revision of consolidated financial forecasts for fiscal year ended March 31, 2022
2. Reason for revision of consolidated financial forecast Forecast of consolidated net sales have been revised upward, as sales of long-listing products and generic drugs has exceeded our forecast due to effect by supply shortage triggered by quality violation stemming from several generic companies.

In terms of profits, gross profit increased owing to better than expected sales and SG&A expenses (including R & D expenses) are expected to be in line with forecast, so we have revised operating income, ordinary income and profit attributable to owners of parent upward.

There is no change to the dividend forecast announced on May 11, 2021 (annual dividend of 52 yen per share).Supplementary material

1. About Consolidated Net Sales
2. About Main Product Sales

On April 26, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the 2022 Q2 Investor Summit on Tuesday, May 3, 2022, at 12:30 p.m. ET at the Westin New York Grand Central, New York, N.Y (Press release, Cytori Therapeutics, APR 26, 2022, View Source [SID1234612963]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator. A webcast of the presentation will be available under the For Investors tab of the Plus website at www.plustherapeutics.com. A webcast replay will also be accessible for 90 days following the event.

On April 26, 2022 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, reported a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC) (Press release, NexImmune, APR 26, 2022, View Source [SID1234612979]). The research will focus on the use of NexImmune’s adoptive cell therapy, AIM ACT, in Columbia’s patient-derived organoid (PDO) models of HPV-associated cancers, including head and neck squamous cell carcinoma. Columbia scientists Hiroshi Nakagawa, MD, Associate Professor of Medicine, and Brian Henick, MD, Assistant Professor of Medicine, will lead the research. Dr. Anil Rustgi, Director of HICCC, will join Drs. Nakagawa and Henick in the investigations. HICCC is an NCI designated cancer center that is at the forefront of discovery science, translational medicine, clinical trials, clinical care and community outreach.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"HPV-associated cancers remain an area with a large unmet medical need," said Dr. Jerry Zeldis, Executive Vice President, R&D of NexImmune. "Our collaboration with Columbia University Irving Medical Center will continue to help us develop new therapies for those patients that are not adequately treated and cured with existing standard of care."

"Our labs have pioneered the development and characterization of PDO systems that resemble the primary tumor, both phenotypically and genotypically," said Dr. Nakagawa. "Using these PDOs, we will seek to rapidly assess the therapeutic potential of NexImmune’s patient-derived T cells in HPV-associated tumors and precancerous cells."